tetano
Editor, Senior Moderator
Int J Immunopathol Pharmacol
. 2024 Jan-Dec:38:3946320241260295.
doi: 10.1177/03946320241260295. Prevalence of cutaneous manifestations and myositis-specific antibodies in COVID-19 patients and Anti-PL7 antibodies association with pulmonary radiological severity: A retrospective study
Giorgio Alberto Oddenino[SUP] 1 2 [/SUP], Paola Canepa[SUP] 2 [/SUP], Emanuele Cozzani[SUP] 1 2 [/SUP], Giulia Gasparini[SUP] 1 2 [/SUP], Alessandro Garlaschi[SUP] 2 3 [/SUP], Luca Roccatagliata[SUP] 2 3 [/SUP], Irene Schiavetti[SUP] 4 [/SUP], Aurora Parodi[SUP] 1 2 [/SUP]
Affiliations
Background: Dermatomyositis (DM) is an idiopathic immune-mediated myopathy, and may involve many organs, including muscles, skin and lungs. Myositis-specific autoantibodies (MSAs) are a useful aid in diagnosis DM and identifying its clinical subtype. During the COVID-19 pandemic, several studies found clinical similarities regarding lung involvement in both COVID-19 and DM. Such similarities have prompted speculation of a common pathogenetic mechanism. Indeed, viral infections are well-known triggers of autoimmune diseases. This prompted us to investigate whether circulating MSAs could be markers of the severity of lung involvement and of clinical outcome in COVID-19 patients. Moreover, we investigated the presence of cutaneous signs of DM in COVID-19 patients.
Methods: We conducted a retrospective cohort study on 178 hospitalized patients affected by COVID-19. The diagnosis was confirmed by naso-pharyngeal swab positivity for SARS-CoV-2. The severity of lung involvement was assessed by assigning to each patient a radiological score ranging from 1 to 4, based on chest imaging (chest X-rays or CT scans). Serum samples were tested for MSAs.
Results: Anti-PL-7 antibodies were detected in 10.1% of patients and were found to be associated with an increased risk of severe pulmonary involvement (p = 0.019) and a worse prognosis in COVID-19 patients. Cutaneous lesions were observed in 26.4% of patients. However, none were cutaneous manifestations of DM.
Conclusions: The detection of anti-PL7 antibodies might predict severe pulmonary involvement and a worse prognosis in COVID-19 patients.
Keywords: COVID-19 patients; anti-PL7 antibodies; dermatomyositis; myositis specific autoantibodies; prognosis.
. 2024 Jan-Dec:38:3946320241260295.
doi: 10.1177/03946320241260295. Prevalence of cutaneous manifestations and myositis-specific antibodies in COVID-19 patients and Anti-PL7 antibodies association with pulmonary radiological severity: A retrospective study
Giorgio Alberto Oddenino[SUP] 1 2 [/SUP], Paola Canepa[SUP] 2 [/SUP], Emanuele Cozzani[SUP] 1 2 [/SUP], Giulia Gasparini[SUP] 1 2 [/SUP], Alessandro Garlaschi[SUP] 2 3 [/SUP], Luca Roccatagliata[SUP] 2 3 [/SUP], Irene Schiavetti[SUP] 4 [/SUP], Aurora Parodi[SUP] 1 2 [/SUP]
Affiliations
- PMID: 39052920
- PMCID: PMC11282529
- DOI: 10.1177/03946320241260295
Background: Dermatomyositis (DM) is an idiopathic immune-mediated myopathy, and may involve many organs, including muscles, skin and lungs. Myositis-specific autoantibodies (MSAs) are a useful aid in diagnosis DM and identifying its clinical subtype. During the COVID-19 pandemic, several studies found clinical similarities regarding lung involvement in both COVID-19 and DM. Such similarities have prompted speculation of a common pathogenetic mechanism. Indeed, viral infections are well-known triggers of autoimmune diseases. This prompted us to investigate whether circulating MSAs could be markers of the severity of lung involvement and of clinical outcome in COVID-19 patients. Moreover, we investigated the presence of cutaneous signs of DM in COVID-19 patients.
Methods: We conducted a retrospective cohort study on 178 hospitalized patients affected by COVID-19. The diagnosis was confirmed by naso-pharyngeal swab positivity for SARS-CoV-2. The severity of lung involvement was assessed by assigning to each patient a radiological score ranging from 1 to 4, based on chest imaging (chest X-rays or CT scans). Serum samples were tested for MSAs.
Results: Anti-PL-7 antibodies were detected in 10.1% of patients and were found to be associated with an increased risk of severe pulmonary involvement (p = 0.019) and a worse prognosis in COVID-19 patients. Cutaneous lesions were observed in 26.4% of patients. However, none were cutaneous manifestations of DM.
Conclusions: The detection of anti-PL7 antibodies might predict severe pulmonary involvement and a worse prognosis in COVID-19 patients.
Keywords: COVID-19 patients; anti-PL7 antibodies; dermatomyositis; myositis specific autoantibodies; prognosis.